Fig. 1From: The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)Consort chart of study participants. Fifty-two patients enrolled between April 2010 and October 2011 received the initial CapeOX plus bevacizumab therapy. The maintenance therapy with capecitabin and bevacizumab was introduced in 45 patients, and oxaliplatine was reintroduced in 29 patients. N, number of patients; CapeOX, capecitabin and oxaliplatin; PD, progression diseaseBack to article page